Disease Info Card

Drug-induced Liver Injury

Information about Drug-induced Liver Injury: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Drug-induced Liver Injury

Most recent studies have shown that Drug-induced Liver Injury shares some biological mechanisms with acute-hepatitis, cholestasis, fatty-liver, hepatic-necrosis, hepatitis, hepatitis-toxic, hepatotoxicity, icterus, inflammation, injury-to-liver, kidney-diseases, liver-cirrhosis, liver-damage, liver-diseases, liver-failure, liver-failure-acute, liver-neoplasms, poisoning, toxic-effect-of-carbon-tetrachloride, tuberculosis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Drug-induced Liver Injury, and have been seen in publications frequently: Cell Activation, Cell Cycle, Cell Death, Cell Proliferation, Coagulation, Conjugation, Cytokine Production, Cytolysis, Excretion, Hepatocyte Proliferation, Hypersensitivity, Immune Response, Inflammatory Response, Liver Regeneration, Localization, Pathogenesis, Regeneration, Secretion, Sensitization, Transport

Quite a number of genes have been found to play important roles in Drug-induced Liver Injury, such as ALB, ALPP, ASRGL1, ATRNL1, CAT, CCL27, CYP2E1, DPAGT1, F2, GGT1, GPT, IL6, NAT10, PDLIM3, SLC17A5, SLPI, SOD1, SORD, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.